Nitrosorbide-Rusphar

Selected form

Isosorbide Dinitrate

Method of action: Antianginal, Cardiac Therapy, Hypotensive, Vasodilator

Treatment option: Coronary Angioplasty, Accelerating Angina, Angioplasty, Heart Attack, Angina Pectoris

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nitrosorbide-Rusphar

Property	Description
Active ingredient	Isosorbide dinitrate (ISDN)
Form	Oral tablet, sublingual tablet, extended-release capsule
Pharmacological class	Organic nitrate, Vasodilator
General purpose	Reduces cardiac workload, improves oxygen supply
Origin	Synthetic, Prescription-only

The Identity and Composition of Nitrosorbide-Rusphar

Nitrosorbide-Rusphar is a synthetic prescription medicine defined by its sole active component, Isosorbide dinitrate (ISDN), which serves as a powerful vasodilator. This drug is a single-ingredient product, widely available in key formulations, including the standard oral tablet, the rapid-onset sublingual tablet, and specialized extended-release capsules or extended-release tablets. The core chemical substance, Isosorbide dinitrate, is clinically recognized for its reliable systemic effects, supporting its use as a foundational medication in its class.

Pharmacological Class: What Type of Vasodilator is ISDN?

This medicine is formally classified as an organic nitrate, a pharmacological group known for its profound effects on blood vessel dilation. The mechanism behind this vasodilator action involves the conversion of Isosorbide dinitrate into nitric oxide (NO) within the body, which signals the vessel smooth muscle to relax and widen. Isosorbide dinitrate is a widely recognized agent in the nitrate class, acting by releasing nitric oxide to cause systemic vasodilation. Due to its established role in clinical practice, Isosorbide dinitrate is included on the Essential Medicines List.

General Purpose and Benefit

The general purpose of this organic nitrate is to fundamentally reduce the workload on the heart by easing circulatory pressure. This is achieved through systemic vasodilation, which results in both a decrease in the volume of blood returning to the heart (reduced preload) and a reduction in the resistance the heart pumps against (reduced afterload). This balancing effect is typically utilized in scenarios requiring enhanced oxygen delivery to the heart muscle. By lessening the heart's effort and simultaneously improving blood flow, the drug provides the essential benefit of restoring a more balanced supply of oxygen to the cardiac muscle.

Regulatory References

What side effects are possible with Nitrosorbide-Rusphar?

Possible Side Effects and Safety Information

The safety profile for Nitrosorbide-Rusphar (Isosorbide dinitrate) is documented in official regulatory sources, with adverse reactions classified by frequency and associated with the drug's vasodilatory effects. The most frequently observed reaction is headache, which is classified as Very Common and is particularly prevalent at the start of treatment.

Other adverse reactions are generally classified based on the affected System-Organ-Class and may include effects on the nervous system and cardiovascular system:

Common Reactions (affecting up to 1 in 10 people): Dizziness, drowsiness, hypotension (low blood pressure), and tachycardia (an increased heart rate).
Uncommon Reactions (affecting up to 1 in 100 people): Nausea, vomiting, allergic skin reactions, severe flushing, and collapse states.

Serious Adverse Reactions and Key Safety Restrictions

Official labeling documents certain serious, though rare, adverse reactions, including severe hypotension that can lead to circulatory collapse or fainting (syncope). A paradoxical worsening of angina has also been noted in rare cases.

Time-Related Safety Pattern: Continuous, high-dose exposure is associated with the development of nitrate tolerance, a safety characteristic noted in regulatory texts that requires a medication-free interval to address.

Population-Specific Notes: Safety considerations are noted for older adults, who may have an increased susceptibility to hypotensive effects. Use also requires caution in individuals with severe hepatic or renal impairment.

Mandatory Safety Restriction: The co-administration of Isosorbide dinitrate with PDE5 inhibitors (used for erectile dysfunction or pulmonary hypertension) is strictly contraindicated due to the critical risk of severe, life-threatening hypotension.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Nitrosorbide-Rusphar

Overdose Scope

Documented overdose presentations: Overdose is documented to present with signs of severe vasodilation and compromised circulation, including a prompt fall in blood pressure, severe hypotension, reflex tachycardia or paradoxical bradycardia, syncope, persistent throbbing headache, dizziness, confusion, vomiting, and later potentially cyanosis or seizures.

Physiological systems affected (as stated in label): The official labeling primarily cites the Cardiovascular system (hypotension, shock, arrhythmia) and the Central Nervous System (headache, vertigo, confusion, convulsions). The Hematologic system is affected through the risk of Methemoglobinemia.

Dose-related or exposure-related factors (if applicable): Overdose typically results from ingestion of a large number of tablets (a massive dose) or from the administration of doses beyond the regulated therapeutic range.

Population-specific overdose notes (if applicable): Patients with underlying cardiovascular disease, those who are volume-depleted, and infants (where a bulging soft spot on the head is a unique reported sign) are specifically noted in overdose contexts.

Emergency-response statements (as written in official documents): Seek immediate medical attention for suspected overdose. Get emergency help immediately if symptoms such as collapse, seizures, or trouble breathing occur.

When immediate medical help is required (label-derived phrasing only): Immediate medical help is required for any suspected overdose, or for symptoms indicative of severe effects, such as a severe fall in blood pressure, loss of consciousness, or the development of cyanosis.

Overdose Classifications (High-Level)

Severity classification (as defined in official documents): The effects are classified as potentially severe or life-threatening, particularly when leading to circulatory shock, coma, or Methemoglobinemia.

Regulatory basis (EMA / FDA / etc.): The overdose profile and required emergency actions are defined in FDA prescribing information, SmPC (EMA), and other national regulatory health authority documents.

Overdose-context constraints (as defined in official documents): The profile is constrained by the two primary documented toxicities: the lack of a specific antagonist for the vasodilatory effects and the need for specific treatment (Methylene Blue) for the toxic complication, Methemoglobinemia.

Resulting Overdose Structure

Official overdose statements:

Overdose is characterized by severe hypotension and signs of circulatory failure, which may include syncope or circulatory shock.
A rare but serious outcome is Methemoglobinemia, which requires the specific antidote, Methylene Blue, to manage the resulting oxygen deficit.
Continuous monitoring of vital signs and supportive treatment are required, including the administration of intravenous fluids and the passive elevation of the patient's legs.
No specific antagonist is known to reverse the primary vasodilatory effects.
Regulators mandate that patients seek immediate medical attention and contact emergency services for any suspected overexposure.

Connection to the overall overdose profile (2–4 sentences): Government regulatory documents define the overdose profile by outlining the cluster of symptoms resulting from acute overexposure, such as severe hypotension and persistent headache. The profile explicitly dictates that immediate medical help must be sought for these specific manifestations due to the potential for life-threatening outcomes like circulatory shock or Methemoglobinemia. Management is officially described as being supportive, focused on reversing hypotension and administering Methylene Blue if required.

Therapeutic Uses of Nitrosorbide-Rusphar

What Nitrosorbide-Rusphar Treats: Main Uses and Benefits

The medication is generally used to help manage two major symptomatic domains related to heart health.

Easing Ischemic Chest Pain (Angina Pectoris)

This medication is commonly used for the long-term prevention of angina pectoris, which involves symptoms related to physical discomfort such as the characteristic squeezing, pressure, or tightness in the chest. It is often applied in contexts involving recurrent or episodic manifestations of chest pain. The primary therapeutic benefit may include a reduction in the frequency and intensity of painful episodes, which contributes to improved day-to-day comfort during symptomatic periods. It is commonly used to help address conditions such as chronic stable angina and is relevant for the long-term management of coronary artery disease.

Supporting Management of Chronic Heart Failure

Nitrosorbide-Rusphar also provides supportive therapeutic benefit as an adjunct for chronic congestive heart failure (CHF). It is relevant in conditions where symptoms related to systemic imbalance, such as shortness of breath or reduced tolerance for activity, interfere with daily functioning due to high cardiac strain. Used in settings where additional symptomatic support is needed, the medication may assist with maintaining functional stability and contributes to easing the overall symptom burden in patients experiencing heightened systemic burden.

Quick Fact: Relief for Cardiac Functional Stress

This medicine is considered relevant in conditions where the heart's workload produces symptoms that create noticeable physiological strain, such as dyspnea on exertion. It may help patients cope more steadily with symptom fluctuations.

Regulatory References

Isosorbide Dinitrate Tablets

Eligibility and Restrictions for Use

Nitrosorbide-Rusphar (Isosorbide Dinitrate) eligibility is defined by strict regulatory criteria, primarily related to concurrent medication use and existing health conditions.

The medicine is contraindicated and must not be used by patients with a known hypersensitivity or allergy to isosorbide dinitrate or any other organic nitrate. Absolute non-eligibility applies to patients concurrently taking Phosphodiesterase type 5 (PDE5) inhibitors (such as sildenafil) or the soluble guanylate cyclase (sGC) stimulator riociguat. Furthermore, use is prohibited in cases of severe hypotension, cardiogenic shock, marked anemia, and conditions associated with increased intracranial pressure.

Eligibility is restricted in certain populations. Pediatric use is not recommended because safety and effectiveness have not been established. Older adults should use the medicine with caution due to the documented risk of orthostatic hypotension. During pregnancy or lactation, use is conditional and requires a determination that the potential benefit justifies the potential risk. Specific conditions like hypertrophic cardiomyopathy or severe hepatic or renal disease require caution and medical supervision.

What should I know about interactions with other medicines?

The official regulatory profile for Nitrosorbide-Rusphar (Isosorbide dinitrate) is dominated by restrictions concerning Pharmacodynamic (PD) interactions that cause severe hypotension. Co-administration with Phosphodiesterase Type 5 (PDE5) Inhibitors (such as sildenafil or tadalafil) and Soluble Guanylate Cyclase (sGC) Stimulators (such as riociguat) is strictly contraindicated. This prohibition is required due to the risk of severe, symptomatic low blood pressure, syncope, or myocardial ischemia resulting from additive vasodilating effects.

A mandatory separation interval is enforced for these agents. Administration of this nitrate must be delayed until 48 hours have elapsed after the last dose of tadalafil, and at least 24 hours after the last dose of sildenafil.

Other medications and substances with known blood pressure effects, including Antihypertensive Drugs, Calcium Channel Blockers, and Alcohol (ethanol), exhibit additive hypotensive effects and may intensify low blood pressure.

Pharmacokinetic (PK) modification is also documented. Interactions involving the CYP3A4 enzyme system may alter the medicine’s exposure: CYP3A4 inhibitors may increase levels, while CYP3A4 inducers may decrease levels according to regulatory data.

Mechanism of Action

Nitrosorbide-Rusphar (Isosorbide dinitrate) is a prodrug that acts by targeting the molecular machinery controlling blood vessel tension. Its physiological consequences result from a cascade initiated by the targeted release of an active physiological signaling molecule.

Molecular Activation: The Nitric Oxide-cGMP Pathway

The drug's action begins inside the vascular smooth muscle cells, where it is enzymatically converted to release Nitric Oxide (NO). NO then activates the enzyme Soluble Guanylyl Cyclase (sGC), which drastically increases the intracellular concentration of the second messenger, cyclic Guanosine Monophosphate (cGMP). This cGMP cascade functions as a molecular signal that strongly modulates the processes required for smooth muscle contraction.

Systemic Effect: Preferential Venodilation and Load Reduction

The final consequence of the cGMP cascade is the relaxation of vascular smooth muscle, resulting in widespread vasodilation. This effect is strongly prioritized in the veins, leading to a significant drop in venous return to the heart. This reduction in the volume and pressure within the heart chambers lowers the heart’s Preload, resulting in a decrease in myocardial wall tension and oxygen demand.

Mechanism Constraint: Nitrate Tolerance

The continuous and frequent engagement of this mechanism can lead to a biological limitation known as nitrate tolerance. This occurs due to impaired bioactivation (a reduction in the cell’s ability to release NO from the drug) and counter-regulatory physiological responses, which lead to a diminished vasodilatory signal over time.

Dosage and Administration Information

Nitrosorbide-Rusphar (Isosorbide dinitrate) is administered using distinct routes and protocols depending on the required clinical purpose. The medicine is approved for oral ingestion (standard and extended-release tablets) for maintenance use and sublingual administration (under the tongue) for situational needs.

The administration schedule for maintenance forms is specifically designed around a mandatory daily dose-free interval, typically lasting at least 14 hours for immediate-release tablets. This scheduled break in dosing is required to preserve the long-term effectiveness of the medication. Dosing for the immediate-release oral form usually begins between 5 mg and 20 mg two or three times a day, with maintenance doses ranging from 10 mg to 40 mg two or three times daily.

Proper administration is form-specific. Extended-release tablets must be swallowed whole and must not be crushed, split, or chewed to ensure the correct sustained-release pattern. Conversely, the sublingual tablet must be placed under the tongue and allowed to dissolve completely, without being swallowed. For older adults, treatment typically begins cautiously at the low end of the dosing range.

Recent Clinical Evidence

Research evidence / Overview of studies for Nitrosorbide-Rusphar

Evidence for Use in Long-term Prevention of Angina Pectoris

Research explored the use of the medicine in relation to chronic stable angina, a condition characterized by fluctuating chest discomfort. Randomized Controlled Trials (RCTs) examined short-term symptom changes, often comparing the medicine against a placebo. These studies focused primarily on outcomes related to physical discomfort and daily functioning in Adults with stable ischemic heart disease.

Research describes patterns where studies reported measurements related to anginal episode frequency following administration of the medicine when defined rest periods between doses were used. Changes measured during the study period often related to exercise capacity, assessed via specific stress tests. These short-term, symptom-based outcomes were typically examined over four weeks to one month.

What remains uncertain is whether use of this medicine as a single agent has an impact on long-term cardiac events or overall survival. Research documents the issue of developing pharmacological tolerance, where the effects may lessen over time. Follow-up durations were limited for fully characterizing long-term durability.

Evidence for Use as Adjunct Therapy in Chronic Heart Failure

Research explored the medicine's use in the context of heart failure, primarily as part of a fixed-dose combination (with hydralazine). This evidence base includes large-scale, long-term RCTs that focused on overall survival and the rate of hospitalization due to heart failure exacerbations.

Large trials monitored mortality and hospitalization rates when the combination was observed in studies over several years. The evidence supporting the evaluation of long-term outcomes is primarily associated with the combination product, not for Nitrosorbide-Rusphar used as a monotherapy. Therefore, data for certain groups remain insufficient when the medicine is used alone.

Key Studies & References

Isosorbide Dinitrate Tablets FDA Label/Monograph (General Use, Tolerance Information, Monotherapy Limitations)

Frequently Asked Questions (FAQ)

Common questions about Nitrosorbide-Rusphar (FAQ)

Q: Is Nitrosorbide-Rusphar used to stop chest pain attacks after they have started?

According to official product information, the regular and extended-release tablets are designated for the long-term prevention of symptoms. Their mechanism of action is not fast enough to treat an acute chest pain attack that has already begun. If the specific product includes the sublingual tablet form, that formulation is typically intended for situational, acute chest pain relief.

Q: Is Nitrosorbide-Rusphar similar to other drugs like Isosorbide Mononitrate or Dinitrate?

Nitrosorbide-Rusphar contains the active ingredient Isosorbide Dinitrate (ISDN). Official sources indicate that both ISDN and Isosorbide Mononitrate are organic nitrates. These drugs are part of the same pharmacological class, which is described as working by relaxing blood vessels.

Q: Do the headaches caused by Nitrosorbide-Rusphar eventually go away?

Regulatory documents describe headaches as a very common side effect, especially when treatment is first initiated. However, clinical patterns described in patient counseling note that these headaches tend to lessen or become less frequent with ongoing use of the medication.

Q: Is it necessary to have a 'drug-free period' when taking Nitrosorbide-Rusphar, and what does the term 'tolerance' mean in relation to using Nitrosorbide-Rusphar for a long time?

Yes, a daily drug-free period is required to minimize the development of a biological limitation called tolerance. Tolerance means that the body's response to the medication may decrease over time, potentially making the drug less effective. This scheduled break helps maintain the intended effect of the medication.

Q: Does Nitrosorbide-Rusphar interact with common pain relievers like Tylenol or ibuprofen?

Official information suggests that simple pain relievers containing Paracetamol (Acetaminophen) are typically compatible with this medication. However, non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen may require special consideration due to the potential to worsen underlying heart-related symptoms.

Q: Are there specific food or beverage interactions mentioned for Nitrosorbide-Rusphar?

The official product information includes a strong caution against consuming alcohol while taking this medication. This is because alcohol is known to increase the risk of side effects, such as dizziness, lightheadedness, and fainting, due to the drug’s enhanced low blood pressure effects.

Q: What conditions would make a person ineligible to take Nitrosorbide-Rusphar, including low blood pressure?

Official contraindications state that this medicine is not eligible for use by patients with a known allergy to nitrates or those concurrently taking PDE5 inhibitors (such as sildenafil). Use is also restricted in cases of very low blood pressure (severe hypotension) or if a patient has recently experienced a heart attack.

Q: Are there any known concerns about using Nitrosorbide-Rusphar during pregnancy or while breastfeeding?

According to official documents, the use of Nitrosorbide-Rusphar during pregnancy or while breastfeeding is designated as conditional. Use in these circumstances requires an individual clinical assessment to determine if the expected benefits justify the potential risks.

Q: Is it normal to see an empty shell in the stool if taking the extended-release form of Nitrosorbide-Rusphar?

When taking the extended-release form of this medicine, seeing a shell or remnant of the tablet in the stool is a known, expected pattern. This is the non-absorbable casing that delivered the medication over time, and it is described in patient counseling materials.

Q: Is there any research evidence on the long-term effects of using Nitrosorbide-Rusphar?

Studies and official information indicate this drug is approved for the chronic, or long-term, prevention of angina (chest pain) due to coronary artery disease. The required daily dose-free interval is a key component of the treatment plan intended to help maintain the drug's effectiveness over time.

Q: Does the medicine help with the shortness of breath that sometimes comes with heart problems?

The medicine may be indicated for use, often alongside other treatments, to manage symptoms associated with congestive heart failure. Its function of reducing the heart's workload may contribute to the improvement of symptoms like shortness of breath.

Q: What is the evidence regarding Nitrosorbide-Rusphar's use in patients with heart failure?

Official medical literature supports the use of this medicine, frequently in combination with other agents, as part of a regimen to manage congestive heart failure symptoms. The drug is described as working to reduce the strain on the heart by relaxing blood vessels.

Q: Why is Nitrosorbide-Rusphar generally taken only once or twice a day?

Official information indicates this medication is generally taken in a pattern that includes a necessary drug-free period each day. This dosing schedule is intended to prevent the medication from losing effectiveness over time due to the development of drug tolerance.

Q: What should I know about taking Nitrosorbide-Rusphar if I have kidney or liver problems?

Official product information advises that use requires caution and medical supervision for patients who have severe liver or kidney problems. Older adults, who may be more likely to have age-related reductions in organ function, are noted as a population requiring special consideration.

Q: Can a patient with glaucoma use Nitrosorbide-Rusphar?

Official warnings note that nitrate medicines have been associated with increased pressure in the eye or around the brain. Patients with a condition involving increased eye pressure (glaucoma) should be aware of this potential association, and any severe headache or blurred vision requires medical evaluation.

Q: What happens if I miss a scheduled dose of Nitrosorbide-Rusphar?

Official patient counseling materials describe the protocol for a missed dose: if remembered soon after the scheduled time, the dose may be taken. However, if it is almost time for the next scheduled dose, the missed dose is to be skipped, and the regular schedule is to be resumed. Regulatory guidance states that double or extra doses should not be taken.

Q: What is the expected time frame for Nitrosorbide-Rusphar to start working after beginning treatment?

According to official pharmacology data, the regular oral tablet typically begins its effect within 20 to 60 minutes of ingestion. The extended-release form has a delayed onset, usually starting to work within about 2 hours to provide a longer duration of action.

Q: What is the risk of developing a serious allergic reaction to Nitrosorbide-Rusphar?

A serious allergic reaction is noted as a possibility in regulatory warnings. Official information states that signs such as hives, difficulty breathing, or swelling of the face, lips, tongue, or throat are cause for immediate emergency medical evaluation.

Q: Does smoking affect how well Nitrosorbide-Rusphar works?

Official patient counseling notes that lifestyle changes, such as modifying smoking habits, may be associated with improved medication outcomes in managing heart conditions. Patients should consult with a doctor to discuss any necessary lifestyle modifications.

Q: Is the tiredness or fatigue some people feel linked to the action of Nitrosorbide-Rusphar?

Official side effect listings confirm that unusual weakness or fatigue is a possible adverse reaction. This symptom is described in labeling as potentially linked to the medicine's effect of reducing blood pressure.

Q: Does Nitrosorbide-Rusphar contain lactose or any other common allergens people ask about?

Certain commercial formulations of isosorbide dinitrate use inactive ingredients like lactose. Due to potential variations between different products, reviewing the specific list of ingredients on the product labeling or with a pharmacist is necessary.

Q: Is it possible to become unwell if I stop taking Nitrosorbide-Rusphar suddenly?

Official product information includes a strong caution against abruptly stopping this medicine. Regulatory warnings indicate that suddenly discontinuing treatment may lead to a greater risk of side effects or a worsening of underlying chest pain symptoms.

Q: Are there specific warnings for patients who have recently had a heart attack?

Official product information states that this medication is contraindicated if a patient is experiencing symptoms consistent with an early heart attack. Use in patients who have recently had a heart attack is noted as requiring close caution and medical supervision.

Q: Are there non-heart-related uses that are mentioned in official documents for Nitrosorbide-Rusphar?

While the primary indications are for heart-related conditions, regulatory monographs indicate that the medicine is also sometimes prescribed for the treatment of severe esophageal spasms.

How should Nitrosorbide-Rusphar be stored and disposed of?

Official Storage Conditions

Isosorbide Dinitrate tablets must be stored at Controlled Room Temperature, which is 20 to 25 C (68 to 77 F), with regulatory allowances for brief temperature excursions up to 30 C (86 F). The product must be protected from light and dispensed in a light-resistant, tight container that is kept tightly closed to maintain stability.

Handling and Child Safety

Storage must ensure the medicine remains out of reach of children, as required by official labeling. There are no additional in-use stability periods or special handling instructions beyond the requirement to avoid excessive heat and light.

Disposal Instructions

Unused or expired Nitrosorbide-Rusphar must be disposed of according to local regulations. Patients should consult local authorities for appropriate pharmaceutical waste handling and disposal programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Russia

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z